1795275-33-0

Basic information

• Product Name: 4-(4-AMino-3-Methyl-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-(4-AMino-3-Methyl-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester;TERT-BUTYL 4-(4-AMINO-3-METHYL-1H-PYRAZOL-1-YL)PIPERIDINE-1-CARBOXYLATE
• CAS NO: 1795275-33-0
• Molecular Formula: C14H24N4O2
• Molecular Weight: 280.36596
• Mol File: 1795275-33-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-AMino-3-Methyl-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-AMino-3-Methyl-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester(1795275-33-0)
• EPA Substance Registry System: 4-(4-AMino-3-Methyl-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester(1795275-33-0)

Safety Data

• Hazardous Substances Data: 1795275-33-0(Hazardous Substances Data)

Upstream product

• 5334-39-4 3-methyl-4-nitro-1H-pyrazole 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 1536200-86-8 tert-butyl 4-(3-Methyl-4-nitro-1H-pyrazol-1-yl)piperidine-1-carboxylate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R)

Optimization of cellular lipophilic ligand efficiency (LLE) in a series of 2-anilino-pyrimidine IGF-1R kinase inhibitors led to the identification of novel 2-(pyrazol-4-ylamino)-pyrimidines with improved physicochemical properties. Replacement of the imidazo[1,2-a]pyridine group of the previously reported inhibitor 3 with the related pyrazolo[1,5-a]pyridine improved IGF-1R cellular potency. Substitution of the amino-pyrazole group was key to obtaining excellent kinase selectivity and pharmacokinetic parameters suitable for oral dosing, which led to the discovery of (2R)-1-[4-(4-{[5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-2-hydroxy-1-propanone (AZD9362, 28), a novel, efficacious inhibitor of IGF-1R.